Patents Issued in November 20, 2018
  • Patent number: 10131915
    Abstract: The present invention is directed to the improved methods for the temporal induction of proteins using the condensed single protein production (cSPP) system.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 20, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Monica Roth, William Schneider, Gaetano T. Montelione, Masayori Inouye, Yuefeng Tang
  • Patent number: 10131916
    Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 20, 2018
    Assignee: Intrexon Corporation
    Inventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
  • Patent number: 10131917
    Abstract: An object of the present invention is to obtain a fermentative yeast having a highly efficient ethanol production without introducing a foreign gene. A further object is to obtain a fermentative yeast that is resistant to proliferation inhibitors such as organic acids, which prevent the proliferation of the fermentative yeast. A yeast having an improved ethanol production ability was generated by introducing transaldolase and alcohol dehydrogenase genes by self-cloning to Meyerozyma guilliermondii that can produce ethanol effectively from pentose and hexose obtained by breeding, and further breeding the resultant yeast.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: November 20, 2018
    Assignee: HONDA MOTOR CO., LTD.
    Inventors: Yoshiki Tsuchida, Ikumi Kurihara, Tomohiro Imai, Iku Koike
  • Patent number: 10131918
    Abstract: An isolated nucleic acid includes a sequence selected from the group consisting of the following: (i) a first nucleotide sequence of SEQ ID NO.: 7, SEQ ID NO.: 3, SEQ ID NO.: 9, or SEQ ID NO.: 5; (ii) a second nucleotide sequence encoding the amino acid sequence of SEQ ID NO.: 6, SEQ ID NO.: 4, SEQ ID NO.: 8, or SEQ ID NO.: 10; and (iii) a third nucleotide sequence complementary to the first nucleotide sequence or the second nucleotide sequence.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: November 20, 2018
    Assignee: National Pingtung University of Science and Technology
    Inventors: Fure-Chyi Chen, Jian-Zhi Huang, Chen-Yu Lee, Ting-Chi Cheng, Shih-Wen Chin
  • Patent number: 10131919
    Abstract: The present invention relates to nucleic acid molecules for use in inducing aponnixis in a plant, transgenic cells, in particular transgenic plant cells, comprising said nucleic acid molecule, transgenic plants, in particular plant seeds, comprising said nucleic acid molecule, methods for inducing apomixis in a plant, methods for the production of apomictic plants and uses thereof.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: November 20, 2018
    Assignee: LEIBNIZ-INSTITUT FUR PFLANZENGENETIK UND KUL TURPFLANZENFORSCHUNG GATERSLEBEN (IPK)
    Inventors: José M. Corral, Timothy Sharbel
  • Patent number: 10131920
    Abstract: There is provided inter alia a DNA construct which comprises a tRNApyl coding sequence and a RNA polymerase III promoter sequence which is capable of acting to express functional tRNApyl sufficiently to support nonsense suppression in a eukaryotic expression system.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Giorgio Dieci, Marcello Marelli, Kenneth H. Grabstein
  • Patent number: 10131921
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: November 20, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Patent number: 10131922
    Abstract: The invention is for an increased isoprenoid production by carotenoid optimization in an expression system and the carotegenic gene for optimization may be geranylgeranyl diphosphate synthase (GGPPS), phytoene synthase (PSY1), conserved CRTI or mutated CRT1A393T, BT1 of S. cerevisae. The carotogenic gene from red yeast which includes Rhodosporidium spp. Rhodotorula spp, Sporidiobolus spp., Leucosporidium spp., Sporobolomyes spp. is selected.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 20, 2018
    Assignee: Indian Institute of Science Education and Research
    Inventors: Manisha Wadhwa, Anand Kumar Bachhawat
  • Patent number: 10131923
    Abstract: The invention relates to a process for the preparation of a fermentation product from ligno-cellulosic material, comprising the following steps: a) optionally pre-treatment of the ligno-cellulosic material; b) optionally washing of the optionally pre-treated ligno-cellulosic material; c) enzymatic hydrolysis of the optionally washed and/or optionally pre-treated ligno-cellulosic material using an enzyme composition comprising at least two cellulase and whereby the enzyme composition at least comprises GH61; d) whereby less than 7.5 mg enzyme composition/g glucan (on dry matter and enzyme as protein) or less than 3.0 mg enzyme composition/g feedstock (on dry matter and enzyme as protein) is used; and e) fermentation of the hydrolyzed ligno-cellulosic material to produce a fermentation product; and f) optionally recovery of a fermentation product; wherein before and/or during the enzymatic hydrolysis oxygen is added to the ligno-cellulosic material.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 20, 2018
    Assignee: DSM IP ASSETS B.V.
    Inventors: Bertus Noordam, Michael Petrus Jozef Berkhout
  • Patent number: 10131924
    Abstract: A process of producing an organic compound and/or an intermediary compound by feeding carbon dioxide to a culture of Cyanobacteria cells and subjecting the culture to light, wherein the cells are capable of expressing a nucleic acid molecule that confers the ability to convert a glycolytic intermediate into said organic/intermediary compound. The expression of the nucleic acid molecule is under the control of a regulatory system which responds to a change in the concentration of a nutrient in the culture.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 20, 2018
    Assignee: PHOTANOL B.V.
    Inventors: Klaas Jan Hellingwerf, Maarten Joost Teixeira de Mattos
  • Patent number: 10131925
    Abstract: There is described a method for producing an ester of 3-hydroxypropionic acid, the method comprising: culturing an Acetobacter lovaniensis bacterium in a growth medium containing phosphate at a level which is more than 1 g/liter, wherein culturing of the bacterium produces the ester of 3-hydroxypropionic acid.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 20, 2018
    Assignee: VERDANT BIOPRODUCTS LIMITED
    Inventor: Irene Finnegan
  • Patent number: 10131926
    Abstract: A transaminase and a use thereof are provided. The transaminase has the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has at least 80% identity to the amino acid sequences as shown in SEQ ID NO: 2 or 4, or has amino acid sequences which are obtained by the substitution, deletion or addition of one or more amino acids and have an the activity of an omega-transaminase with high stereoselective R-configuration catalytic activity, wherein the high stereoselective refers to the content of one of the stereoisomers being at least about 1.1 times that of the other.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 20, 2018
    Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD, ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD, TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD, ASYMCHEM LABORATORIES (FUXIN) CO., LTD, JILIN ASYMCHEM LABORATORIES CO., LTD
    Inventors: Hao Hong, Feng Gao, Yanjun Li, Yan Zhang, Shaohe Li
  • Patent number: 10131927
    Abstract: The present invention discloses an industrial scale method to obtain 1-kestose by the use of a recombinant fructosyltransferase (FTF), isolated from Festuca arundinacea, expressed constitutively in a non-saccharolytic yeast. In this invention, the recombinant FTF type sucrose:sucrose 1-fructosyltransferase (1-SSTrec) is produced constitutively, stable and at high yield, both in the culture supernatant and in intact cells of the host Pichia pastoris. Hence, the invention additionally provides a method for 1-SST production at industrial scale. The recombinant enzyme is then used for mass production of short-chain fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the present invention establishes conditions that allow conversion rates where the synthesized FOS constitute above 55% (w/w) of the total sugars in the reaction mixture and the 1-kestose content reaches values higher than 90% (w/w) of the total FOS fraction.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 20, 2018
    Assignee: CENTRO DE INGENIERIA GENÉTICA Y BIOTECNOLOGIA
    Inventors: Enrique Rosendo Pérez Cruz, Lázaro Hernández García, Duniesky Martínez García, Luis Enrique Trujillo Toledo, Carmen Menéndez Rodríguez, Alina Sobrino Legón, Ricardo Ramírez Ibañez, Gumersindo Feijoo Costa, Juan Manuel Lema Rodicio
  • Patent number: 10131928
    Abstract: Disclosed is a method of preparing pure or substantially pure D-myo-inositol-3-phosphate from glucose-6-phosphate and/or fructose-6-phosphate. The method may also be applied to protected and/or derivative forms of glucose-6-phosphate and/or fructose-6-phosphate so as to form protected/derivative forms of D-myo-inositol-3-phosphate, for use in further chemical reactions. The enzyme D-myo-inositol-3-phosphate synthase (INO1) is contacted with the glucose-6-phosphate and/or fructose-6-phosphate to generate labeled or unlabeled, protected or unprotected D-myo-inositol-3-phosphate, which may be further reacted and/or purified.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 20, 2018
    Assignee: UNIVERSITY COURT OF THE UIVERSITY OF ST ANDREWS
    Inventor: Terry K. Smith
  • Patent number: 10131929
    Abstract: Enzymatic reactions are disclosed herein comprising water, glucose-1-phosphate, cellodextrin, and at least one cellodextrin phosphorylase enzyme comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:6. These reactions produce a low molecular weight, insoluble cellulose with enhanced features.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: November 20, 2018
    Assignee: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Natnael Behabtu, Ayrookaran J. Poulose, Zheyong Yu, Zhenghong Zhang
  • Patent number: 10131930
    Abstract: A method of filtering a liquid sample that includes passing a sample comprising at least one biological organism through a filter membrane at a passive water volume flux of at least 10 L/m2·h·psi, wherein the filter membrane comprises a Bubble Point pore size of no more than 1.0 ?m, thereby retaining at least one biological organism on the surface of the membrane; and detecting the at least one biological organism retained on the surface of the filter membrane.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: November 20, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Patrick A. Mach, Raj Rajagopal, Wensheng Xia, Jinsheng Zhou, Chunmei Guo
  • Patent number: 10131931
    Abstract: A method for determining whether bacteria in a sample obtained from a subject at a point of care in a clinical setting is susceptible to an antibiotic, within a time period associated with a point of care. The method includes measuring a bioluminescent indication from a first test sample based on released ATP to determine a characteristic associated with the bioluminescent indication and comparing the characteristic associated with the bioluminescent indication to a first threshold. The method includes determining whether a bacteria is present by comparing the difference between a characteristic associated with a first confirmatory bioluminescent signal and a characteristic associated with a second confirmatory bioluminescent signal to an confirmatory threshold.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 20, 2018
    Assignee: RONALD TURNER
    Inventor: Ronald Turner
  • Patent number: 10131932
    Abstract: A method of determining generation of an activated protease in a biological sample is provided. The method comprises the steps of exposing a biological sample to a substrate for the activated protease, wherein the substrate comprises a detectable label linked to a cleavage sequence for the activated protease by C-terminal and N-terminal spacers that form a beta-sheet, and wherein the detectable label emits a first signal associated with the substrate and second signal associated with a cleaved product; and determining the generation of the activated protease by measuring the change in the first or second signal over time.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 20, 2018
    Assignee: McMaster University
    Inventors: Shengjun Qiao, Peter Gross
  • Patent number: 10131933
    Abstract: The present invention relates to materials and methods suitable for determining the presence or amount of Botulinum toxin (BoNT) in a test sample by means of a luminescence assay in which the substrate peptide is composed of: an amino acid sequence susceptible to proteolytic cleavage by BoNT, an amino acid sequence corresponding to a reporter domain encoding a fluorescent or bioluminescent polypeptide, and a tag suitable for attaching the substrate peptide to a suitable support, preferably by covalent bond.
    Type: Grant
    Filed: September 3, 2012
    Date of Patent: November 20, 2018
    Assignee: Albert-Ludwigs-Universitaet Freiburg
    Inventors: Gregory Stevens, Michael Krueger, Andrea Zgaga-Griesz, Gerald Urban, Dalice Silver
  • Patent number: 10131934
    Abstract: A method for carrying out nucleic acid amplification reactions using a microfluidic device is described. Amplification primers and other amplification reagents are deposited at a plurality of reaction sites in the device, a sample solution containing amplifiable polynucleotides is introduced into the reaction sites, and amplification is carried out.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: November 20, 2018
    Assignee: Fluidigm Corporation
    Inventors: Marc Unger, Ian D. Manger, Michael Lucero, Yong Yi, Emily Miyashita-Lin, Anja Wienecke, Geoffrey Facer
  • Patent number: 10131935
    Abstract: Parallel isolation of a double-stranded nucleic acid and a single-stranded nucleic acid is possible from a sample that contains these acids, without separating the acids, by mixing the sample with a lysis buffer having high salt concentration or low salt concentration, or having a proteolytic enzyme. The sample that contains nucleic acid before its lysis, or the sample that has already been lysed or homogenized, is adjusted with a binding buffer in such a manner that the total nucleic acid is adsorbed onto a solid carrier. The binding buffer contains at least one non-ionic detergent in a high concentration. With the exception of the detergent, the sample contains no other non-acidic organic component miscible in water. The carrier with the adsorbed total nucleic acid is removed. The adsorbed total nucleic acid is washed and eluted.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: November 20, 2018
    Assignee: AJ INNUSCREEN GmbH
    Inventor: Timo Hillebrand
  • Patent number: 10131936
    Abstract: According to the present teachings, methods and compositions are provided that utilize at least one reference dye of formula (I): In some embodiments, a method comprises measuring a detection signal of a reporter dye and at least one reference dye of formula (I). In some embodiments, a composition comprises a reference dye of formula (1), a buffer, a selection of nucleotides and a protein.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: November 20, 2018
    Assignee: Life Technologies Corporation
    Inventors: Scott C. Benson, Cinna Monighetti, Sandy M. Koepf
  • Patent number: 10131937
    Abstract: The present invention provides assays systems and methods for detection of chromosomal abnormalities and status of single loci associated with monogenic or polygenic traits in a sample containing nucleic acids from a maternal and a fetal source.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 20, 2018
    Assignee: ARIOSA DIAGNOSTICS, INC.
    Inventors: Andrew Sparks, Arnold Oliphant, Jacob Zahn, Ken Song, John Stuelpnagel
  • Patent number: 10131938
    Abstract: The present invention is directed to a method of designing a plurality of capture oligonucleotide probes for use on a support to which complementary oligonucleotide probes will hybridize with little mismatch, where the plural capture oligonucleotide probes have melting temperatures within a narrow range. The present invention further relates to an oligonucleotide array comprising of a support with the plurality of oligonucleotide probes immobilized on the support, a method of using the support to detect single-base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences, and a kit for such detection, which includes the support on which the oligonucleotides have been immobilized.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 20, 2018
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Francis Barany, Monib Zirvi, Norman P. Gerry, Reyna Favis, Richard Kliman
  • Patent number: 10131939
    Abstract: Methods and compositions for the amplification of nucleic acids and generation of concatemers are disclosed. Amplification methods provided herein may be performed under isothermal conditions. Methods and compositions may include reagents such as nucleic acid polymerases and primers.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 20, 2018
    Assignee: Theranos IP Company, LLC
    Inventors: Kamila Belhocine, Josephine Lee, Pranav Patel, Aaron Richardson, Scott Tabakman
  • Patent number: 10131940
    Abstract: Described is a method for quantifying nucleic acid in a nucleic acid amplification reaction, in which an asymmetric nucleic acid amplification reaction is performed on a sample such that double stranded nucleic acid product is generated in an initial stage of the reaction, and single stranded nucleic acid product is generated in a subsequent stage of the reaction once a limiting primer is exhausted. Relative amounts of double stranded nucleic acid product and single stranded nucleic acid product produced are then detected by means of a melt curve analysis. The ratio of double stranded product peak height to single stranded product peak height may then be used to quantify the amount of starting template based on the ratio of double stranded product peak height to single stranded product peak height.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: November 20, 2018
    Assignee: Epistem Limited
    Inventor: Ben Cobb
  • Patent number: 10131941
    Abstract: An application of thiolated single-stranded DNA enhances specific amplification of polymerase chain reaction, namely a method for enhancing specific amplification of polymerase chain reaction by utilizing thiolated single-stranded DNA, which includes the following step: adding an appropriate amount of the thiolated single-stranded DNA into a PCR system to perform PCR amplification, wherein the appropriate amount means that the final concentration of the thiolated single-stranded DNA in a 20 ?L reaction system is not less than 15 ?M. The thiolated single-stranded DNA meets the following conditions: the thiolated single-stranded DNA is one segment of any sequence which is non-complementary and non-homologous to a target sequence; the Tm value is not less than 37.7° C.; and at least one end contains a thiolalkyl group SH—C6H12—.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: November 20, 2018
    Assignee: INSTITUTE OF PLANT PROTECTION, SHANDONG ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Xingbo Lu, Guangyuan Zhang, Hongwei Sun, Fan Li, Shuke Yang, Rui Gao, Xiaohui Xu
  • Patent number: 10131942
    Abstract: Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: November 20, 2018
    Assignee: INTERPACE DIAGNOSTICS CORPORATION
    Inventors: Eric Matthew Gayle Ellsworth, Sydney David Finkelstein, Sara Ann Jackson, Brendan Corcoran, Dennis Morgan Smith, Jr.
  • Patent number: 10131943
    Abstract: A target polynucleotide is expanded. In respect of each nucleotide in the target polynucleotide, the target polynucleotide comprises clock nucleotides and at least one signal nucleotide in a predetermined order. The clock nucleotides have a predetermined sequence common to each nucleotide in the target polynucleotide. The at least one signal nucleotide is characteristic of the identity of the respective nucleotide in the target polynucleotide. During translocation of the expanded polynucleotide through a nanopore, electrical measurements dependent on the polynucleotide within the pore are made, to derive an analysis signal. Clock signals derived from the clock nucleotides are identified. Relative to the positions of the identified clock signals, nucleotide signals derived from the least one signal nucleotide are derived to analyze the target polynucleotide.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 20, 2018
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: Stuart William Reid, Gavin Harper
  • Patent number: 10131944
    Abstract: The invention also encompasses novel structures and methods comprising providing a molecular adapter for capture and manipulation of transfer RNA. The adaptor is bound to a tRNA molecule. The adaptor may be a cholesterol-linked DNA adapter oligonucleotide. The invention is useful in sequencing, identification, manipulation and modification of tRNA.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: November 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Bernick, Andrew Smith
  • Patent number: 10131945
    Abstract: The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 20, 2018
    Assignee: Natera, Inc.
    Inventors: Matthew Rabinowitz, George Gemelos, Milena Banjevic, Allison Ryan, Zachary Demko
  • Patent number: 10131946
    Abstract: A method is provided for characterizing a lipofilling agent causing increased lipofilling activity in adipose tissue from a target body area. Such a method can include obtaining a plurality of distinct preadipocyte cultures taken from a plurality of distinct body areas of an individual, exposing the plurality of distinct preadipocyte cultures to a plurality of potential lipofilling agents, culturing the plurality of distinct preadipocyte cultures through differentiation to form a plurality of distinct adipocyte cultures, measuring a degree of lipofilling activity of adipocytes from each of the plurality of distinct adipocyte cultures, and quantifying the measured lipofilling activity across the plurality of distinct adipocyte cultures to identify a lipofilling agent causing increased lipofilling activity in adipose tissue from the target body area as compared to adipose tissue in the non-target body area.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: November 20, 2018
    Assignee: NSE Products, Inc.
    Inventors: Dale Kern, Jin Namkoong
  • Patent number: 10131947
    Abstract: The present invention provides assay systems and methods for determining the percent fetal contribution of cell-free DNA in a maternal sample from a pregnant female with an egg donor pregnancy. Further provided, are assay systems and methods for determining a statistical likelihood of the presence or absence of a fetal aneuploidy in a maternal sample using a determined percent fetal cell-free DNA in the sample.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 20, 2018
    Assignee: ARIOSA DIAGNOSTICS, INC.
    Inventors: Arnold Oliphant, Eric Wang, Craig Struble
  • Patent number: 10131948
    Abstract: A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 20, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Joshua M. Hare, Bettina Heidecker
  • Patent number: 10131949
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 20, 2018
    Assignee: Celera Corporation
    Inventors: Yonghong Li, Steven Schrodi, Ann Begovich, Monica Chang
  • Patent number: 10131950
    Abstract: Method and kits for diagnosing propensity to non-contact cranial cruciate ligament rupture (CCLR) in a dog are described. The method includes isolating genomic DNA from a dog and then analyzing the genomic DNA from step for a single nucleotide polymorphism occurring in selected loci that have been determined to be associated with the CCLR phenotype via a genome-wide association study.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peter Muir, Lauren Baker
  • Patent number: 10131951
    Abstract: The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: November 20, 2018
    Assignee: ARIOSA DIAGNOSTICS, INC.
    Inventors: Andrew Sparks, Arnold Oliphant, Jacob Zahn, Ken Song, John Stuelpnagel
  • Patent number: 10131952
    Abstract: Disclosed herein are compositions and methods for monitoring hematopoietic reconstitution or suppression in a subject. Also disclosed are compositions and methods for reconstituting the hematopoietic compartment of a subject in need thereof. Also disclosed is a method for monitoring the effect of ionizing radiation on the lung in a subject. Also disclosed is the ability to use detection of the one or more microRNA indicative of radiation-induced lung injury to guide therapy of the subject. Also disclosed is the ability to use detection of the one or more microRNA indicative of radiation-induced lung injury to evaluate the efficacy of a lung treatment following radiation exposure.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 20, 2018
    Assignee: Ohio State Innovation Foundation
    Inventors: Naduparambil Jacob, Arnab Chakravarti
  • Patent number: 10131953
    Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David Frazier Jarrard, Bing Yang
  • Patent number: 10131954
    Abstract: Methods and kits for detection and quantification of EGFRvIII in the peripheral blood for monitoring the therapy of a GBM patients.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: November 20, 2018
    Assignee: University of Cincinnati
    Inventors: Olivier Rixe, El Mustapha Bahassi
  • Patent number: 10131955
    Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 20, 2018
    Assignee: PACIFIC EDGE LIMITED
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Patent number: 10131956
    Abstract: The present invention provides a marker used for detecting colon cancer, and also provides application of said marker in the detection of colon cancer, as well as an associated kit and detection method.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: November 20, 2018
    Assignee: SHENZHEN GENEBIOHEALTH CO. LTD.
    Inventors: Haoyang Yu, Mianqiao Chen
  • Patent number: 10131957
    Abstract: The present invention provides breast cancer markers based on RECQL mutations, and related methods, uses, agents, and kits. The invention includes methods for determining the susceptibility of a subject to developing breast cancer, and methods for detecting, diagnosing, treating, and predicting responses to treatment for breast cancer.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 20, 2018
    Assignee: Women's College Hospital
    Inventor: Mohammad R. Akbari
  • Patent number: 10131958
    Abstract: The disclosure provides for methods, compositions, and kits for multiplex nucleic acid analysis of single cells. The methods, compositions and systems may be used for massively parallel single cell sequencing. The methods, compositions and systems may be used to analyze thousands of cells concurrently. The thousands of cells may comprise a mixed population of cells (e.g., cells of different types or subtypes, different sizes).
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: November 20, 2018
    Assignee: Cellular Research, Inc.
    Inventors: Christina Fan, Stephen P. A. Fodor, Glenn Fu, Geoffrey Richard Facer, Julie Wilhelmy
  • Patent number: 10131959
    Abstract: A method of diagnosing bacterial vaginosis in a woman, which involves determining an amount of each of more than one BV-associated bacterium in a vaginal sample obtained from the female and assessing a BV status of the female based on the amount of each of the more than one BV-associated bacterium in the sample.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 20, 2018
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Charles Paul Cartwright, Bryndon Denae Lembke, Kalpana Ramachandran
  • Patent number: 10131960
    Abstract: Described herein are novel fluorescent sensors for Diacyl Glycerol (DAG) and phosphatidylinositol 4,5-bisphosphate (PIP2) that are based on circularly permuted fluorescent proteins. These sensors use less visible spectrum than FRET-based sensors, produce robust changes in fluorescence, and can be combined with one another, or with other sensors, in a multiplex assay on standard fluorescent plate readers or live cell imaging systems.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: November 20, 2018
    Assignee: Montana Molecular LLC
    Inventors: Thomas E. Hughes, Paul H. Tewson, Anne Marie Quinn
  • Patent number: 10131961
    Abstract: The invention refers to viable biomining microorganisms encapsulated in alginate capsules, called BioSigma Bioleaching Seeds or BBS, wherein the alginate capsules have iron (II) and/or iron (III) ions as the cross-linking cations, and the usage of these capsules in the inoculation of these microorganisms in bioleaching processes.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 20, 2018
    Assignee: BIOSIGMA S.A.
    Inventors: Patricio Ernesto Martinez Bellange, Pilar Angelica Parada Valdecantos
  • Patent number: 10131962
    Abstract: A seamless steel pipe has a carbon equivalent Ceq of 0.50% to 0.58%, and contains specified carbides containing Mo at a ratio of 50 mass % or more, V, and at least one selected from the group consisting of Ti and Nb, and having a size of 20 nm or more.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: November 20, 2018
    Assignee: NIPPON STEEL & SUMITOMO METAL CORPORATION
    Inventors: Yuji Arai, Kenji Kobayashi, Hiroyuki Nagayama
  • Patent number: 10131963
    Abstract: The invention relates to a pneumatic needling device for the local surface treatment, more particularly fastening, of components, comprising a first and a second needle (2) that can move in a needle direction; a first and a second piston chamber (3) for applying pneumatic pressure to the first and second needles in the needle direction; a pressure supply (1) that can be connected to and disconnected from the piston chambers, more particularly as a result of a movement of the needles in the needling device; a pressure recording means (5) for measuring pressure fluctuations in the piston chambers; and a control means (6) designed to carry out a reaction on the basis of the measured pressure fluctuations.
    Type: Grant
    Filed: April 5, 2014
    Date of Patent: November 20, 2018
    Assignee: MTU Aero Engines AG
    Inventors: Janne Ehrl, Holger Polanetzki
  • Patent number: 10131964
    Abstract: An austenitic steel sheet excellent in resistance to delayed cracking is provided. The composition of said steel comprises in weight: 0.35%?C?1.05% 15%?Mn?26% Si?3% Al?0.050% S?0.030% P?0.080% N?0.1%, at least one metallic element X chosen among vanadium, titanium, niobium, molybdenum, chromium 0.050%?V?0.50%, 0.040%?Ti?0.50% 0.070%?Nb?0.50% 0.14%?Mo?2% 0.070%?Cr?2%. The composition may optionally include B, Ni and/or Cu. The remainder of the composition includes iron and unavoidable impurities inherent to fabrication, including hydrogen. The quantity Xp of the at least one metallic element under the form of carbides, nitrides or carbonitrides is, in weight: 0.030%?Vp?0.40% 0.030%?Tip?0.50% 0.040%?Nbp?0.40% 0.14%?Mop?0.44% 0.070%?Crp?0.6%. The hydrogen content Hmax designating the maximal hydrogen content that can be measured from a series of at least five specimens, and the quantity Xp, in weight, is such that: 1000 ? H max X P ? 3.3 .
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 20, 2018
    Assignees: ARCELORMITTAL FRANCE, THYSSENKRUPP STEEL EUROPE AG
    Inventors: Colin Scott, Philippe Cugy, Christian Allely